Related Experiment Video
Updated: Sep 22, 2025

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
Published on: September 16, 2022
Liquid biopsy: expanding the frontier of circulating biomarker discovery and validation in breast cancer
Philip C Miller1, Dorraya El-Ashry2,3, Marc E Lippman1
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington DC, WA 20007, USA.
Abstract:
Liquid biopsies represent an attractive, minimally-invasive alternative to surgical sampling or complex imaging of breast cancer and breast cancer metastasis. Here we present a summary of the major biomarker components often evaluated in liquid biopsy samples from patients with breast cancer, including circulating tumor cells, circulating cell-free tumor DNA, and cancer-associated plasma proteins. We discuss recent advancements in methods of detection and use of these biomarkers in breast cancer. Finally, we highlight some of our own recent contributions to breast cancer liquid biopsy, including the identification and characterization of circulating Cancer Associated Fibroblasts.

